RemeGen Co., Ltd. announced a private placement of 70,763,170 A shares at a issue price of CNY 36.035694 per share for the gross proceeds of up to CNY 2,550,000,000 on March 29, 2024. The target subscribers for the placement will be not more than 35 subscribers. The transaction has been approved by the board of the company and is subject to the approval of Shareholders at the EGM, the approval of the Shanghai Stock Exchange and the approval of registration by the CSRC.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.3 HKD | +1.10% | +7.67% | -13.75% |
04-26 | RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-04 | Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.75% | 3.55B | |
+2.93% | 108B | |
+8.82% | 105B | |
+3.17% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B |
- Stock Market
- Equities
- 9995 Stock
- News RemeGen Co., Ltd.
- RemeGen Co., Ltd. announced that it expects to receive CNY 2.549999941 billion in funding